A Case with Severe Endometriosis, Ovarian Hyperstimulation Syndrome, and Isolated Unilateral Pleural Effusion after IVF by Sopa, Negjyp et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
A Case with Severe Endometriosis, Ovarian Hyperstimulation Syndrome, and Isolated
Unilateral Pleural Effusion after IVF
Sopa, Negjyp; Larsen, Elisabeth Clare; Andersen, Anders Nyboe
Published in:
Case Reports in Obstetrics and Gynecology
DOI:
10.1155/2017/8243204
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Sopa, N., Larsen, E. C., & Andersen, A. N. (2017). A Case with Severe Endometriosis, Ovarian Hyperstimulation
Syndrome, and Isolated Unilateral Pleural Effusion after IVF. Case Reports in Obstetrics and Gynecology, 2017,
[8243204]. https://doi.org/10.1155/2017/8243204
Download date: 03. Feb. 2020
Case Report
A Case with Severe Endometriosis, Ovarian Hyperstimulation
Syndrome, and Isolated Unilateral Pleural Effusion after IVF
Negjyp Sopa, Elisabeth Clare Larsen, and Anders Nyboe Andersen
The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Correspondence should be addressed to Negjyp Sopa; negjyp.sopa@regionh.dk
Received 13 January 2017; Revised 26 April 2017; Accepted 12 June 2017; Published 10 July 2017
Academic Editor: Julio Rosa-e-Silva
Copyright © 2017 Negjyp Sopa et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We present a very rare case of right-sided isolated pleural effusion in a patient with severe endometriosis who, in relation to in vitro
fertilization (IVF), developed ovarian hyperstimulation syndrome (OHSS). Earlier laparotomy showed grade IV endometriosis
including endometriotic implants of the diaphragm.The patient had no known risk factors for OHSS and only a moderate number
of oocytes aspirated. She received, however, repeated hCG injections for luteal support. The patient did not achieve pregnancy but
was hospitalized due to pain in the right side of the chest and dyspnoea. A chest computed tomography (CT) showed a pleural
effusion on the right side. Total of 1000ml of pleural fluid was drained after a single thoracentesis. After three days, the symptoms
and fluid production ceased. Ascites is a common finding in OHSS, but pleural effusions are rare. Further, isolated pleural effusions
have not previously been described in a patient with endometriosis. We suggest that the repeated hCG injections induced effusions
from the endometriotic lesions at the diaphragm and as a consequence this patient developed isolated hydrothorax.
1. Case Report
The case is a 29-year-old woman with a history of grade IV
endometriosis and infertility. In 2011, she had surgery twice
where endometrioses were diagnosed in the pelvic organs,
the bowel, and the diaphragm. In 2015, she was referred to
the Fertility Clinic after 1 year of infertility. Anti-Mullerian
hormone (AMH) was 15 pmol/L. Initially, three intrauterine
inseminations were done followed by IVF treatment with a
standard antagonist protocol, where she received follitropin
alpha (Gonal-f) 150 IU daily for eight days. Choriongo-
nadotropin (hCG; Ovitrelle) 6500 IU was given to induce
ovulation. Nine oocytes were collected from eleven follicles.
Two blastocysts were transferred and luteal support was given
using vaginal progesterone. She did not become pregnant
and did not develop OHSS. The second IVF treatment
involved an antagonist protocol with Menotropin (hMG;
Menopur) 187.5 IU daily for 7 days. To induce ovulation she
now received hCG (Pregnyl) 10.000 IU. Five follicles were
aspirated, and four oocytes were retrieved. On day 2, one
embryo was transferred and she did not become pregnant.
In the luteal phase, vaginal progesterone was supplemented
with hCG 1500 IU every third day. Three doses were given.
Thirteen days after the second oocyte retrieval, the patient
was hospitalized primarily due to pain in the right side of
the chest and dyspnoea. Initial examination by a cardiologist
revealed tachypnea, dyspnoea, and tachycardia. Saturation
was 100%, respiratory rate was 18/min, there was no rise
in temperature, pulse was 82 beats/min, and blood pressure
was 120/83mmHg. There was no abdominal distension or
ascites and no signs of thrombosis of the lower or upper
extremities. Electrocardiogram (ECG) and blood tests were
normal except for slightly elevated leukocytes 12.6 × 109/l. On
suspicion of pulmonary embolism, a computed tomography
(CT) was made, showing a pleural effusion on the right side.
There were no signs of pulmonary embolism (Figure 1).
The patient was then transferred to the gynecological
department and admitted due to suspicion of OHSS. A pelvic
ultrasound showed enlarged ovaries on both sides measuring
5,7 cm × 3,9 cm (right ovary) and 7,8 cm × 6,3 cm (left
ovary) and a minimal amount of ascites. Thoracentesis was
performed in local anesthesia by ultrasound guidance. A 7F
pigtail catheter was introduced. Total 1.000ml of clear yellow
pleural fluid was drained during thoracentesis. Analysis of
the sample showed negative cytological test for endometriotic
cells and culture showed no signs of infection (bacteria and
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fungi). The patient received low molecular weight heparin
Innohep (Tinzaparin) 4500 IU subcutaneous prophylacti-
cally for 10 days.
After 3 days, the symptoms and fluid production ceased,
and repeated chest X-ray showed no pleural effusion (Fig-
ure 2).
The patient recovered completely and was discharged.
2. Discussion
To our knowledge, this is the first case of OHSS with pleural
effusion as the only clinical manifestation in a young woman
undergoing IVF due to severe endometriosis. According to
evidence-based Danish Clinical Guidelines, our case was
classified as having a mild degree of OHSS since the largest
ovarian measurement was less than eight cm [1, 2].
OHSS is a relatively common iatrogenic complication
to controlled ovarian stimulation occurring in 0.5–5% of
women undergoing IVF [3, 4]. The syndrome normally
presents with ovarian enlargement and an acute fluid shift
into extravascular spaces primarily causing accumulation of
ascites in the abdomen. The pathogenesis is partly related to
increased vascular permeability [5]. Risk factors are women
with polycystic ovarian syndrome (PCOS), a high ovarian
reserve, that is, elevated levels of anti-Mullerian hormone
(AMH) and a high antral follicle count (AFC), previous
OHSS, young age, high doses of rFSH, high number of
oocytes collected, and high oestradiol levels at the end of
stimulation [6]. Additionally luteal support using repetitive
doses of hCG is known to increase the risk of OHSS,
as reviewed by Fatemi et al. [7], and substantiated in
the Cochrane Systematic Review including 94 randomised
controlled trials comparing different luteal phase support
regimens. The conclusion was that the use of repeated hCG
injections as luteal support does increase the risk of OHSS
[8].
Our case had none of the OHSS risk factors, except that
she was exposed to repeated hCG injections. Further, in her
first ART cycle, she had no OHSS or pulmonary complaints
despite the fact that more oocytes were retrieved. She did
however not receive repeated hCG injections in her first ART
cycle.
HCG has multiple actions, including effects on the
endometrium and endometrial angiogenesis during early
implantation [9] Further, hCG stimulates corpus luteum to
produce progesterone but also to some degree estrogenwhich
is known to activate and maintain endometriosis. As such
the endometriotic implants at the diaphragm may have been
stimulated repeatedly by exogenous hCG and thus caused
the effusion. Apposing this explanation is that her abdominal
endometriosis did not cause effusions and thus ascites.
Severe OHSS is estimated to occur in 1% of women
undergoing IVF [10, 11]. Symptoms include massive ascites,
decreased effective blood volume, oliguria, thromboembolic
complications, pleural and pericardial effusions, and some-
times even death. The occurrence of pleural effusion, that is,
hydrothorax in patients with OHSS, is below 10% [10].
Endometrial implants, such as at the diaphragm, pleura,
and pericardium, are uncommon. The cause of such implan-
tation sites is unknown, but the theories include metaplas-
tic transformation, lymphatic, hematogenous, and transdi-
aphragmatic migration [12, 13]. Thoracic endometriosis syn-
drome (TES) is a rare and complex disease, but nonetheless it
is well described [13]. Symptoms include haemothorax, pneu-
mothorax, and haemoptysis. TES in relation to IVF has been
described in two case reports. In the first case, the patient
presentedwith earlyOHSS three days after oocyte retrieval. A
chest computed tomography showed bilateral pleural effusion
and a subsequent thoracentesis revealed hemorrhagic pleural
fluid. This case had 30 oocytes retrieved and developed
OHSS with hemorrhagic pleural effusion as described above
[14]. The second case developed pneumothorax after in vitro
fertilization and embryo transfer. She had 13 oocytes collected
[15].
Pleural effusion without intra-abdominal ascites is an
extremely rare presentation of OHSS [16]. The first case of
isolated pleural effusion associated with OHSS was described
in 1975 [17]. Since then only few case reports have been
published and none of these cases had endometriosis [17–20].
As described previously, pleural effusionmainly occurs in the
severe forms ofOHSS and in general togetherwith other signs
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of OHSS. Predominantly, pleural effusion develops on the
right side [21], the explanation being that lymphatic drainage
may differ between the two sides and that the diaphragmatic
recess is greater on the right side. It is also a possibility
that pleural effusion is derived from a liquid shift from
abdominal ascites [21, 22]. To our knowledge, there are no
data explaining why pleural fluid does not drain into the
abdominal cavity.
To conclude, we hypothesize that this patient, who had
only 4 oocytes aspirated, developed isolated hydrothorax as
a result of repeated hCG injections in the luteal phase. The
theory behind this is that the exogenous hCG stimulated the
endometriotic lesions at the diaphragm and as a consequence
induced the pleural effusion. As the patient did not achieve
pregnancy, her symptoms ceased when exogenous hCG was
withdrawn.
3. Summary
We present a rare manifestation of OHSS, more specifically
isolated pleural effusion. Furthermore, it developed in an
endometriosis patient with a rather low response to con-
trolled ovarian stimulation The patient was however given
repetitive doses of hCG, which is known to increase the risk
ofOHSS.The pleural effusionmay be caused by hCG induced
stimulation of the endometriotic lesions on the diaphragm
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